Eli Lilly (LLY)

1,271.80
+46.07 (3.76%)
NYSE· Last Trade: Aug 19th, 12:20 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,225.73
Open1,245.81
Bid1,271.04
Ask1,272.56
Day's Range1,240.54 - 1,292.65
52 Week Range685.15 - 1,249.45
Volume2,303,569
Market Cap1.22T
PE Ratio (TTM)55.42
EPS (TTM)22.9
Dividend & Yield6.920 (0.54%)
1 Month Average Volume2,618,565

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Absci (ABSI) Q2 2026 Earnings Call Transcriptfool.com
Biotech extends runway to 2028 with $100M financing and Eli Lilly deal.
Via The Motley Fool · August 19, 2026
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
News Provided by USA News Group on behalf of MindWalk Holdings Corp.
By USA News Group · Via GlobeNewswire · August 19, 2026
Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Marketinvestors.com
The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion obesity market.
Via Investor's Business Daily · August 19, 2026
Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’benzinga.com
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
Via Benzinga · August 19, 2026
Why Eli Lilly (LLY) Stock Is Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...
Via StockStory · August 18, 2026
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?fool.com
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.
Via The Motley Fool · August 18, 2026
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
Issued on behalf of Conexeu Sciences Inc.
By Equity Insider · Via GlobeNewswire · August 18, 2026
PPH vs. IYH: Which Healthcare Fund Is the Better Buy?fool.com
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.
Via The Motley Fool · August 18, 2026
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Nowfool.com
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
Via The Motley Fool · August 18, 2026
U.S. Physical Therapy Names Nchacha Etta as Chief Financial Officer /www.snipesohttpstokemonkeycom
Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana
Via Talk Markets · August 18, 2026
If I Were in My 20s, I'd Buy This Unstoppable Vanguard ETF and Hold It Foreverfool.com
Investors can reap big rewards over the long term by betting on growth in their younger years.
Via The Motley Fool · August 18, 2026
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.
Via AB Newswire · August 17, 2026
Why Is Omniab Stock Rallying After Eli Lilly Deal?benzinga.com
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Via Benzinga · August 17, 2026
Wall Street Says the Stock Market's Return Will Crush the Long-Term Average in the Next Yearfool.com
The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.
Via The Motley Fool · August 17, 2026
1 of Wall Street’s Favorite Stocks on Our Watchlist and 2 We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Via StockStory · August 17, 2026
2 GLP-1 Stocks That Could Double Your Money by 2031fool.com
They are fairly risky, but their potential upside is massive.
Via The Motley Fool · August 16, 2026
Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patientfool.com
The company's peers in the pharmaceutical industry should be worried.
Via The Motley Fool · August 15, 2026
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)fool.com
They are way more than just GLP-1 stocks.
Via The Motley Fool · August 14, 2026
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Biggerfool.com
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.
Via The Motley Fool · August 14, 2026
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?fool.com
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.
Via The Motley Fool · August 14, 2026
Amphastar (AMPH) Q2 2026 Earnings Call Transcriptfool.com
New product launches drove 5% revenue growth and margin expansion.
Via The Motley Fool · August 13, 2026
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?fool.com
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.
Via The Motley Fool · August 13, 2026
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK?fool.com
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.
Via The Motley Fool · August 13, 2026
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunityfool.com
The stock continues to look unstoppable.
Via The Motley Fool · August 13, 2026
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?fool.com
It's yet another setback for the drugmaker.
Via The Motley Fool · August 13, 2026